UnitedHealth Group Q2: The Real Test Begins Now (Downgrade)

UnitedHealth Group Incorporated delivered a strong Q2, with improved medical care ratio and operating income up 50% YoY, signaling effective cost initiatives. UNH raised FY 2026 EPS guidance to $19.5–$20, reflecting operational recovery and solid cash flow prospects, especially from Optum’s AI-driven growth. Despite operational improvements, UNH’s valuation now trades above its 5-year average P/E, reducing risk-reward asymmetry and margin of safety. I downgrade UNH from Buy to Hold, as current multiples and shareholder yield no longer justify a bullish stance given ongoing sector complexities.